Genetesis, part of the CT portfolio, has been selected for Spoke Membership in the ARPA-H Investor Catalyst Hub! This opens doors to funding and opportunities to shape how ARPA-H tackles crucial health challenges. 🌟

Why Mark Cuban And Others Are Betting $40 Million On This Under 30 Start Up trib.al/BAsHkRQ

As AI rewires our world, I spoke to Fast Company about how medicine is changing, and how Proscia is becoming the "AWS of Pathology"

A novel case series in American Heart Journal Plus exploring the value of MCG for myocarditis assessment. Congrats Bettina Heidecker and team on this very exciting new paper! sciencedirect.com/science/articl…

High-dose testosterone treatment may have promoted myocarditis. Magnetocardiography detected it. sciencedirect.com/science/articl…

🚀 Exciting News Alert! 🚀 Mark Cuban and other savvy investors are putting their money where it matters, betting $40 million on this under-30 start-up! We can't help but agree, as we're proud to have Genetesis as a part of our portfolio. forbes.com/sites/zoyahasa…

MICRO 2.0 begins! ✅

Thrilled to be part of such a great team Genetesis , revolutionizing the standard of care for noninvasive diagnosis of CMD using MCG. #MedicalImaging #HealthcareInnovation #magnetocardiography

The MICRO trial is officially published in AHJPlus! A very exciting first of its kind study in partnership with The Christ Hospital - H&V Institute - WHC, Cleveland Clinic and Ascension St. John! sciencedirect.com/science/articl…

Yet another CardioFlux paper out today in AHJPlus! This one demonstrates the promise of MCG to detect physiological changes just hours after revascularization: sciencedirect.com/science/articl…

Amazing and thankful to see so many incredible investigators partnering with us on our pivotal #MICRO2 trial Genetesis cc: Cleveland Clinic, Saint Luke's Ascension St. John And many more partners to be featured soon!

📷📷Yet another paper out on CardioFlux, this time showcasing the first ever national cost savings analysis potential of MCG! This paper is a collab between researchers at Brigham and Women's Hospital , Cleveland Clinic and Ascension St. John Read more here: sciencedirect.com/science/articl…

How can more widespread use of magnetocardiography help us better care for our ED chest pain patients? This quick, noninvasive test can identify those eligible for early discharge, saving downstream costs and valuable time in the hospital. Read more here: doi.org/10.1016/j.ahjo…

In 2014, Forbes highlighted that the U.S. wastes over $500 million/yr on inappropriate stress tests: forbes.com/sites/larryhus… Now, 10 years later Christopher Baugh MD shows how #magnetocardiography can completely reverse the damage (and improve quality while doing it!). Exciting!

#MICRO2 is nicely underway, but we continue to add and announce new partner sites: Today, Genetesis is thrilled to share that The Christ Hospital - H&V Institute - WHC and Mountainside Medical Center have enrolled their first patients! Congrats to PIs Odayme Quesada, MD and Ankitkumar Patel MD MPH FACC FSCAI RPVI and their wonderful teams!

Two very interesting #magnetocardiography cases in ER chest pain patients published today in AHJPlus: sciencedirect.com/science/articl… Congrats to lead author Dr. Sharon Mace of the Cleveland Clinic on yet another great paper!

Congratulations to #MasonOH partner @GenetesisINC and their MICRO2 study team at Mayo Clinic on enrolling their first MICRO2 patient! Their advancements in cardiology research have global impact, and they’re being made right here in our community. #MasonLovesBio #TechHub

CardioFlux is now approved in Canada 🇨🇦 It is indicated for the diagnosis of #ischemia, and this newly granted medical device license is a landmark victory for #magnetocardiography, as this is the FIRST clinical approval of an MCG device, ever. prnewswire.com/news-releases/…

We are thrilled to announce that Health Canada has officially approved CardioFlux MCG for the diagnosis of myocardial ischemia! 🎉 This milestone marks the first approval of an MCG device in Canadian regulatory history. genetesis.com/press-releases…

Raptor Group portfolio company Genetesis has announced that Health Canada has officially approved CardioFlux MCG for the diagnosis of myocardial ischemia. This marks the first approval of an MCG device in Canadian regulatory history 👋